Polypeptide and application thereof in preparation of medicine for treating lung cancer

By optimizing the parent peptide and lipid modification, a new type of peptide was obtained, which solved the problems of insufficient targeting, high toxicity and strong resistance of polypeptide drugs in the prior art in the treatment of NSCLC, and achieved the synergistic effect of the combined use of polypeptides and chemotherapeutic drugs, significantly improving the cure rate of lung cancer.

CN119708151APending Publication Date: 2025-03-28GENLOCI BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311246428.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-26
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

The prior art has problems such as insufficient targeting, high systemic toxicity, and strong drug resistance when treating non-small cell lung cancer (NSCLC), and polypeptide drugs face limitations in hemolytic activity and stability when used in vivo.

Method used

By optimizing the parent peptide, using solid phase synthesis method and lipid modification, a new type of polypeptide was obtained with the amino acid sequence of GRFKRFRKFKKLFKKLSK-C18. This peptide can be used in combination with chemotherapeutic drugs such as doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt), reducing toxic side effects and increasing sensitivity to kill tumor cells.

Benefits of technology

This polypeptide has significant cytotoxicity to tumor cells, significantly inhibits the migration of lung cancer cells, and does not cause a hemolytic reaction. When used in combination with chemotherapy drugs, there is a synergistic effect, especially when combined with DTX, which significantly improves the cure rate of lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119708151A_ABST
    Figure CN119708151A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicine, in particular to polypeptide and application thereof in preparation of medicine for treating lung cancer. The polypeptide is obtained by optimizing the length and sequence of a parent peptide chain and carrying out lipidation modification on the C end of the peptide chain. The polypeptide has certain cytotoxicity to lung cancer cells, can inhibit migration of the lung cancer cells, and does not cause hemolytic reaction; in-vivo experiments show that the polypeptide has an anti-tumor effect, and the tumor volume is obviously reduced along with the prolonging of time, so that the polypeptide is further proved to have the effect of directly killing or inhibiting tumors; in addition, the polypeptide can be combined with common chemotherapeutic drugs for use, has a synergistic effect, and has an optimal effect when being combined with DTX.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to polypeptides and their application in preparing drugs for treating lung cancer. Background Art

[0002] Lung cancer is one of the most common malignant tumors in the world. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for about 80%~85% of all lung cancers (Sung, H., Ferlay, J., Siegel, RL et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidenceand Mortality Worldwide for 36 Cancers in 185 Countries CA. Cancer J. Clin.71, 209–249. https: / / doi.org / 10.3322 / caac.21660.). Due to the latest developments in cancer treatment, the mortality rate of lung cancer patients has steadily decreased, but it is still the highest (Lu, T., Yang, X., Huang, Y., et al., 2019. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag. Res. 11, 943–953. https: / / doi.org / 10.2147 / CMAR.S187317.). With existing treatments, the 5-year survival rate of stage I NSCLC patients is approximately 80%, while the survival rate of stage II to III patients is 13-60%. Surgical resection is the treatment of choice for patients with stage I, II, and some stage IIIA disease (Goldstraw P, Chansky K, Crowley J, et al. The IASLCLung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.). Although surgery is usually more effective than systemic radiation therapy in removing all disease, it is not appropriate for everyone.For some patients with poor nutritional status and other major cardiopulmonary diseases, the risks of surgery are extremely high and it is difficult to ensure the safety of the surgery. Even with a comprehensive preoperative examination and evaluation, some common serious complications such as infection, bleeding, local injury, and even cardiac arrest, stroke or thrombosis cannot be completely avoided (Hou Shihao. Study on the effect and mechanism of bee venom peptide on the proliferation of human non-small cell lung cancer A549 cells [D]. Supervisor: Wei Zhongheng. Youjiang Medical College for Nationalities, 2022.).

[0003] Other treatments, such as chemotherapy and immunotherapy, often lack specificity (i.e., tumor targeting), leading to systemic toxicity and eventual drug resistance, limiting the options for cancer treatment (Pucci, C., Martinelli, C., Ciofani, G., 2019. Innovative approaches for cancer treatment: current perspectives and new challenges. ecancermedicalscience 13. https: / / doi. org / 10.3332 / ecancer.2019.961); combination therapy is also a treatment option, but not all drug combinations can have a synergistic effect.

[0004] Studies have shown that the inhibitory effect of peptide P161 combined with cisplatin (DDP) on the proliferation of various tumor cells is poor, and the combined drug group has the best effect on mouse breast cancer MA-782; (Zhang Mengyi, Zheng Heng, Chen Ying, Chen Jianhua. Inhibitory effect of peptide P161 combined with cisplatin on the proliferation of various tumor cells [J]. Medical Guide, 2014, (10): 1288-1290.); Hang Haifang et al. found that As2O3 and 8-CPT-cAMP can inhibit the growth of U266 cells and induce apoptosis, but the CI value of the combination of the two drugs is greater than 1 when analyzed by CompuSyn software, indicating that the synergistic effect of As2O3 and 8-CPT-cAMP in inhibiting the proliferation of U266 cells is not obvious. In addition, the morphology of U266 cells treated with single drugs and the combination of the two drugs for 72 hours showed typical apoptotic manifestations such as nuclear condensation and apoptotic bodies, and there was no significant change in the cell morphology of the single drug group and the combination drug group. (Hang Haifang, Wang Yingying, Tang Yong, et al. Experimental study on arsenic trioxide combined with cyclic adenosine monophosphate mimetics to induce apoptosis of myeloma cells [J]. Chinese Journal of Oncology, 2019, 29(3):5. DOI:10.19401 / j.cnki.1007-3639.2019.03.002.). Therefore, new drugs or treatment strategies are urgently needed to improve the global disease burden of non-small cell lung cancer.

[0005] Peptides have attracted great interest as an alternative to traditional cancer therapies. Cationic antitumor peptides have many advantages over other chemical agents, including low molecular weight, relatively simple structure, greater cytotoxicity to tumor cells than healthy cells, fewer side effects, easy absorption, and low risk of inducing multidrug resistance (Zandsalimi, F., Talaei, S., Noormohammad Ahari, M., et al., 2020. Antimicrobial peptides: apromising strategy for lung cancer drug discovery? Expert Opin. Drug Discov. 15, 1343–1354. https: / / doi.org / 10.1080 / 17460441.2020.1791080). Peptides can selectively target cancer cells, and their cationic and amphipathic properties facilitate rapid internalization through anionic phospholipid cancer cell membranes. In addition, peptides exhibit a faster mechanism of action through independent inhibitory pathways, reducing the possibility of drug resistance (Kunda, NK, 2020. Antimicrobial peptides as novel therapeutics for non-small cell lung cancer. Drug Discov. Today 25, 238–247. https: / / doi.org / 10.1016 / j.drudis.2019.11.012.).

[0006] Although peptides show strong anticancer activity, the number of studies reporting the potential of peptides for treating NSCLC is limited. Most peptides are limited by hemolytic activity, and many peptides only work in vitro.

[0007] Ting et al. found that the cationic peptide derived from Nile tilapia (Oreochromis niloticus) - tilapia fish (TP4) showed broad cytotoxicity towards non-small-cell lung cancer cells, but the molecule had strong hemolytic activity (Ting CH, Chen J Y. Nile Tilapia derived TP4 shows broad cytotoxicity toward to non-small-cell lung cancer cells[J]. Marine Drugs, 2018, 16(12):506.); Li et al.'s research showed that one of the cationic peptides, Temproin-1CEa, is a naturally occurring cationic α-helical antimicrobial peptide that has effective anticancer effects and moderate hemolytic activity; (Li S, Li Y, Liu Y, et al. Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer[J]. International Journal of Molecular Sciences, 2023, 24(10):8642.); Ilaria Serra et al. derived a cationic peptide from frogs Pseudhymenochirus merlini Hymenochirin-1Pa (LKLSPKTKDTLKKVLKGAIKGAIAIASMA-NH 2 ), a host defense peptide isolated from the skin secretions of Pipidae, exhibits broad-spectrum antimicrobial activity, including against Staphylococcus aureus, Acinetobacterand multidrug-resistant clinical isolates of Stenotrophomonas maltophilia with high efficacy. The peptide also showed high cytotoxicity against human non-small lung adenocarcinoma A549 cells, breast cancer MDA-MB-231 cells and colorectal adenocarcinoma HT-29 cells, but its therapeutic potential as an anticancer drug was limited by its moderate hemolytic activity (Serra I, Scorciapino MA, Manzo G, et al. Conformational analysis and cytotoxic activities of the frog skin host-defense peptide, hymenochirin-1Pa[J]. Peptides, 2014, 61: 114-121.); Milena Mechkarska (Mechkarska M, Attoub S, Sulaiman S, et al. Anti-cancer, immunoregulatory, and antimicrobial activities of the frog skin host-defense peptides pseudhymenochirin-1Pb and pseudhymenochirin-2Pa[J]. Regulatory Peptides, 2014, 194: 69-76.) et al. also showed high cytotoxicity against human non-small lung adenocarcinoma A549 cells, breast cancer MDA-MB-231 cells and colorectal adenocarcinoma HT-29 cells, but its therapeutic potential as an anticancer drug was limited by its moderate hemolytic activity (Serra I, Scorciapino MA, Manzo G, et al. Conformational analysis and cytotoxic activities of the frog skin host-defense peptide, hymenochirin-1Pa[J]. Peptides, 2014, 61: 114-121.); Milena Mechkarska et al. also showed high cytotoxicity against human non-small lung adenocarcinoma A549 cells, breast cancer MDA-MB-231 cells and colorectal adenocarcinoma HT-29 cells, but its therapeutic potential as an anticancer drug was limited by its moderate hemolytic activity (Serra I, Scorciapino MA, Manzo G, et al. Conformational analysis and cytotoxic Pseudhymenochirus merlini Two host defense peptides, Pseudhymenochirin-1Pb (Ps-1Pb) and pseudohymenochirin-2Pa (Ps-2Pa), were isolated from the skin secretions of Pipidae. Related studies have shown that Ps-1Pb and Ps-2Pa are highly cytotoxic to non-small cell lung adenocarcinoma A549 cells, breast cancer MDA-MB-231 cells, and colorectal adenocarcinoma HT-29 cells (LC 50 < 12 μM), but also had hemolytic effect on human erythrocytes; in addition, Ps-1Pb and Ps-2Pa showed potent in vitro cytotoxicity against a variety of human tumor cell lines, but studies on their in vivo cytotoxicity have not been reported.

[0008] It can be seen that peptide drugs need to overcome many limitations in cancer research, including hemolytic activity, specificity of peptides for target tumor cells, stability under physiological conditions, and finding the optimal dose and route of administration to obtain high concentrations of peptides at the target site to induce therapeutic effects. Summary of the invention

[0009] In view of the deficiencies in the prior art, the first aspect of the present invention is to provide a polypeptide.

[0010] The applicant disclosed a polypeptide (i.e., a mother peptide, amino acid sequence: MGRFKRFRKKFKKLFKKLS) in a previously submitted patent application. The mother peptide has extremely strong anti-inflammatory and antimicrobial effects and is widely used in the fields of biomedicine, biotechnology, daily chemical product technology, and ecological protection. The applicant has now optimized the mother peptide and obtained the polypeptide of the present invention by solid phase synthesis and lipid modification. The amino acid sequence of the polypeptide is SEQ ID NO.1. The optimized polypeptide has high stability and anti-tumor activity, and can be used in combination with different first-line anti-tumor drugs to reduce toxic side effects and increase the sensitivity of killing tumor cells, thereby improving the overall cure rate. The second aspect of the present invention is to provide a use of a polypeptide in the preparation of a drug for treating lung cancer.

[0011] In particular, the polypeptide can be used in combination with any one or a combination of alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immunosuppressants, doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt), preferably DOX, DTX, or Pt.

[0012] The third aspect of the invention is to provide a pharmaceutical composition comprising the polypeptide according to claim 1.

[0013] Particularly, the composition further comprises a pharmaceutically acceptable excipient.

[0014] Particularly, the dosage form of the composition includes oral preparations or injections.

[0015] Particularly, the oral preparations include tablets, capsules, granules, pills, syrups, sprays, aerosols, oral solutions, oral suspensions or oral emulsions.

[0016] Particularly, the injection preparation includes injection solution or powder injection.

[0017] In particular, the polypeptides can be used in combination with chemotherapeutic drugs.

[0018] Particularly, the chemotherapy drugs include alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immunosuppressants, and any one or a combination of doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt), preferably DOX, DTX, or Pt.

[0019] The present invention has the following advantages and effects compared with the prior art: The present invention provides a polypeptide for treating lung cancer, which has certain cytotoxicity to tumor cells, significantly inhibits cell migration of lung cancer, and does not cause hemolytic reaction; in vivo experiments, the polypeptide has anti-tumor effect, and the tumor volume changes more obviously with the extension of time, further proving that the polypeptide has a direct killing or tumor inhibition effect; in addition, the polypeptide can be used in combination with common chemotherapy drugs, all of which have synergistic effects, and the combination with DTX has the best effect. The present invention provides an experimental basis for the treatment of lung cancer and has broad application prospects for clinical treatment of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The cytotoxicity graphs of the parent peptide and the polypeptide acting on A549 cells for 24 h and 48 h are shown; Figure 2 The cytotoxicity graphs of the parent peptide and the polypeptide acting on H292 cells for 24 h and 48 h are shown; Figure 3 The cytotoxicity graphs of the parent peptide and polypeptide acting on H460 cells for 24 h and 48 h are shown; Figure 4 The cytotoxicity graphs of the parent peptide and the polypeptide acting on H1299 cells for 24 h and 48 h are shown; Figure 5 The cytotoxicity graphs of the parent peptide and polypeptide acting on H1703 cells for 24 h and 48 h are shown; Figure 6 The cytotoxicity graphs of the parent peptide and polypeptide acting on H1975 cells for 24 h and 48 h are shown; Figure 7 The cytotoxicity graphs of the parent peptide and the polypeptide acting on SK-MES-1 cells for 24 h and 48 h are shown; Figure 8 The cytotoxicity graphs of the parent peptide and polypeptide acting on BEAS-2B cells for 24 h and 48 h are shown; Fig. 9 It indicates the results of cell scratch test at 0-48 h; Fig.10 A line graph showing changes in cell migration rate over time; Fig.11 Indicates the results of hemolysis test; Fig.12 It represents the changes of nude mouse body weight and tumor volume over time; Fig.13 It indicates the weight and size of the tumor after dissection; Fig.14 It indicates the cytotoxicity of DOX, DTX and Pt on A549 cells; Fig.15A dosage curve diagram showing the combined use of chemotherapy drugs and peptides; Fig.16 Represents the relationship between the inhibition rate (Fa) and the combination index (CI) or dose reduction index (DRI). DETAILED DESCRIPTION

[0021] One embodiment of the present invention provides a polypeptide; based on the parent peptide, the polypeptide of the present invention is obtained by optimizing the length and sequence of the peptide chain and adding 18-carbon stearic acid at the C-terminus of the peptide chain. The amino acid sequence of the polypeptide is SEQ ID NO.1.

[0022] Another embodiment of the present invention provides a use of a polypeptide in preparing a drug for treating lung cancer.

[0023] In particular, according to the clinical judgment of the doctor, the polypeptide can be used in combination with any one or a combination of alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immunosuppressants, doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt), preferably DOX, DTX, or Pt.

[0024] Another embodiment of the present invention provides a pharmaceutical composition, which contains the polypeptide according to claim 1.

[0025] In particular, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0026] Pharmaceutically acceptable excipients refer to excipients and additives used in the production of drugs and the preparation of prescriptions. They refer to substances that have been reasonably evaluated in terms of safety and are included in pharmaceutical preparations in addition to active ingredients. The same pharmaceutical excipient can be used in pharmaceutical preparations for different routes of administration and has different effects and uses. The pharmaceutically acceptable excipients added to the drugs provided by the present invention can play a role in shaping, acting as a carrier or improving stability. In addition, they also have important functions such as solubilization, solubilization or sustained release.

[0027] Typical but non-limiting pharmaceutically acceptable excipients include: one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adherents, antioxidants, chelating agents, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids or release retardants.

[0028] Particularly, the dosage form of the pharmaceutical composition includes oral preparations or injections.

[0029] In particular, the oral preparations include, but are not limited to, tablets, capsules, granules, pills, syrups, sprays, aerosols, oral solutions, oral suspensions or oral emulsions.

[0030] The carriers used in tablets generally include lactose and corn starch, and lubricants such as magnesium stearate may also be added. The diluents used in capsules generally include lactose and dry corn starch. Oral suspensions are usually mixed with the active ingredients and suitable emulsifiers and suspending agents.

[0031] Optionally, some sweeteners, flavoring agents or coloring agents may be added to the above oral preparation forms.

[0032] In particular, the injection preparation includes but is not limited to injection solution or powder injection.

[0033] Among them, the carriers and solvents that can be used include water, Ringer's solution and isotonic sodium chloride solution. Fixed oils can also be employed as a solvent or suspending medium such as mono- or diglycerides.

[0034] In particular, the polypeptides can be used in combination with chemotherapeutic drugs.

[0035] In particular, the chemotherapy drugs include alkylating agents such as nimustine, carmustine, lomustine, cyclophosphamide, ifosfamide, glyphosate mustard, etc.; antimetabolites such as doxifluridine, docefluridine, 6-mercaptopurine, cytarabine, fluguanidine, tegafur, gemcitabine, carmofur, hydroxyurea, methotrexate, eufodine, ancitabine, etc.; antitumor antibiotics such as actinomycin, aclarubicin, epirubicin, mitomycin, pelocycin, bleomycin, pirarubicin, etc.; plant anticancer drugs such as irinotecan, Con, harringtonine, hydroxycamptothecin, vinorelbine, paclitaxel, taxotere, topotecan, vincristine, vindesine, vinblastine, etc.; hormones such as atamestane, anastrozole, anluamide, letrozole, formestane, medroxyprogesterone acetate, tamoxifen, etc.; immunosuppressants, other anticancer drugs such as asparaginase, dacarbazine, oxaliplatin, oxadiazine, coplatin, mitoxantrone, procarbazine carboplatin, cisplatin, doxorubicin, docetaxel, etc., and any pharmaceutical salts, acids or derivatives of the above substances.

[0036] The polypeptides of the present invention can be formulated into pharmaceutical compositions and various administration forms suitable for the administration route selected by the patient, such as oral or intravenous, intramuscular, topical or subcutaneous parenteral administration. The amount and combination of the compound will vary, depending on the nature of the drug linker, the drug load, the degree of internalization caused by the cell surface, the transduction and release of the drug, the type of disease, the patient's condition, such as age, sex, weight, etc., and ultimately determined by the attending physician or clinician.

[0037] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art. In the examples, the reagents added are all commercially available unless otherwise specified.

[0038] As used in the context of the present invention, the term "treatment" is used to refer to obtaining a desired pharmacological and / or physiological effect, such as inhibiting cancer cell growth, causing cancer cell death, or improving a disease or condition. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers the treatment of diseases (mainly cancer) in mammals, especially humans, including: (a) preventing the occurrence of a disease (e.g., preventing cancer) or a condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the development of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a pharmaceutical composition to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing a polypeptide as described herein to an individual in need.

[0039] Example 1: Preparation of polypeptide Solid phase organic synthesis method, Fmoc-protected amino acid strategy, SPPS solid phase synthesis technology are used to synthesize straight-chain peptides, and the target products are obtained by cleavage, oxidation and purification.

[0040] 1) Solid phase synthesis: Wang Resin (1.0 mmol / g) S=0.3mmol / g was used, and the Fmoc-process was adopted to sequentially condense the amino acids from the C-terminus to the N-terminus (from right to left) according to the amino acid sequence of the polypeptide of the present invention to obtain a resin peptide.

[0041] 2) Peptide resin cleavage: Preparation of cleavage reagent: Calculate the amount of cleavage reagent based on the volume of 1g peptide resin to 15ml±2ml: TFA:H2O:EDT:Tis =95:1:2:2. Sequentially add the required cleavage reagents H2O, TFA, EDT, and Tis to the cleavage reaction bottle, and control the temperature of the cleavage reagents at 0-10°C; add the cleavage reagents to the peptide resin under stirring, and after the system temperature stabilizes; then control the temperature at 20-25°C and stir the reaction for 2 hours. Filter out the cleavage solution, precipitate it with 5 times the volume of the concentrated solution in ice ether, filter out the precipitate and dry it under reduced pressure at room temperature to obtain a crude product.

[0042] 3) Oxidation: Grind the crude product, prepare purified water, slowly add the ground crude product under stirring, and at the same time add acetonitrile aqueous solution. When the crude product is completely dissolved, add dilute ammonia water to adjust the pH value of the solution to 7.5-8. Take samples every half an hour and send them to QC for mass spectrometry to determine whether the oxidation is complete.

[0043] 4) Purification and freeze-drying: The completely oxidized sample is filtered through a 0.45um microporous filter membrane; the crude product is purified by Shimadzu semi-preparative and 5cm, 10um, C-18 column filler, separated and purified at room temperature using a suitable gradient, the target product is collected, and the qualified main peak is freeze-dried under reduced pressure to obtain powdered impurities.

[0044] The amino acid sequence of the polypeptide SEQ ID NO.1 of the present invention is as follows: GRFKRFRKKFKKLFKKLSK-C18, wherein C18 in the sequence is stearic acid, which is connected to the amino group of the lysine side chain at the carbon end of the polypeptide.

[0045] Example 2: CCK-8 method to detect the cytotoxicity of the polypeptide of the present invention to various lung cancer cells 160 μg / mL of the parent peptide and the polypeptide solution of the present invention were prepared and diluted respectively. Cells A549, H1299, H1975, SK-MES-1, H1703, H460, H292, and BEAS-2 that were grown in the logarithmic growth phase of DMEM culture medium containing 10% serum and passaged more than twice were cultured at 2×10 3 ~3×10 3 The cells were uniformly inoculated in a 96-well plate at a density of 100 / well. After 24 hours of overnight attachment, the two prepared peptide solutions were added, with at least 3 replicates for each concentration. A blank group (complete medium only), a control group (cells and complete medium), and an experimental group (cells, drugs, and complete medium) were set up. After the addition of drugs, the 96-well plate was placed in an incubator and cultured for 48 h and 72 h. CCK-8 was added to the complete medium and prepared at a ratio of 10% CCK-8. The old medium in the 96-well plate was discarded and the CCK-8 solution was added. After 2.5 h, the absorbance of the cells at a wavelength of 450 nm was detected by an ELISA instrument.

[0046] Cell proliferation rate and half inhibitory concentration (IC 50 ) According to the cell growth rate = (OD experimental - OD blank) / (OD control - OD blank) × 100% GraphPad Prism 8 was used to plot dose-response curves and IC 50 The selectivity index (SI) is the value of TC 50 / IC 50The selection index is greater than 1.00 for effective, and the larger the index, the greater the safety range. It is calculated by the following formula: Selection index = IC50 value of normal cells from tissues similar to tumor cell lines / IC50 of tumor cell lines. The results are as follows Figure 1-8 As shown in the results, the two polypeptides have a killing effect on 7 lung cancer cell lines in a concentration-dependent manner, but the toxicity of different cells is different, indicating that the polypeptides have a certain selectivity in anti-tumor activities; among them, the anti-tumor effect of the mother peptide in the 7 cell lines is generally better than that of the polypeptide of the present invention, and the effect on A549 is the most significant, with the highest selection index of 4.969; in the polypeptide group of the present invention, A549 and SK-MES-1 have obvious dosage advantages, and the selection index is relatively high, which are 1.557 and 2.075, respectively (Table 1). Since the A549 cell line is sensitive to both polypeptides, and NSCLC accounts for about 80% to 85% of human lung cancer, A549 cells were selected for subsequent experimental studies.

[0047] Table 1 IC values ​​of two peptides against eight cell types 50 value Cell Mother peptide Peptides <![CDATA[IC 50 (μg / mL)]]> SI <![CDATA[IC 50 (μg / mL)]]> SI A549 13.88 4.969 39.72 1.557 H1299 16.11 4.281 78.76 0.785 H1975 31.09 2.218 82.61 0.7489 H460 13.90 4.961 76.21 0.8118 H292 37.78 1.825 1266 0.0488 SK-MES-1 25.86 2.667 29.81 2.075 H1703 19.23 3.5865 71.19 0.869 BEAS-2B 68.97 - 61.87 - Example 3: Effect of polypeptide on migration of A549 lung cancer cells Take out two 6-well plates, use a ruler and a marker to draw several intersecting straight lines under each well, with a spacing of 0.5-1 cm between each horizontal line, take two 10 cm dishes full of A549 cells, digest and centrifuge, resuspend, and evenly plate in 6-well plates, set up 3 parallel groups, and then add 1640 complete medium to the 6-well plates, so that the total volume of each well is 3 mL. When it is observed that the cells in the well plate cover the bottom of the 6-well plate, use a 200 μL pipette tip to draw lines along the pre-made marks. After the drawing, discard the culture medium and wash slowly with PBS twice to wash away the crossed cells. The control group added 3 mL of serum-free culture medium, and the experimental group added 3 mL of serum-free fresh culture medium containing a peptide concentration of 10 μg / mL. Set the time points of 0 h, 24 h, and 48 h, and take photos under the microscope when the time points are reached. At 0 h, find the clearest scratch in each well and determine the position, and fix it at the site for photo observation at the subsequent time points.

[0048] The results are as follows Fig. 9 , 10 As shown, the mother peptide group had a large degree of cell migration at 24 h, and the scratch gap was significantly reduced at 48 h. The control group had a certain degree of cell migration at 24 h and 48 h, while the polypeptide group had basically no cell migration, and even inhibited cell migration.

[0049] Example 4: Hemolysis Experiment Take 4 clean glass test tubes and number them. Tube 1 is the positive control tube, tube 2 is the negative control tube, and tubes 3-4 are the test sample control tubes. Add 2% red blood cell suspension, 0.9% sodium chloride solution, and purified water in sequence as shown in the table below. After mixing, immediately place in a constant temperature box at 37℃±0.5℃ for incubation. Observe the hemolysis and agglutination reaction after 3 hours.

[0050] The test sample was prepared with 0.9% saline at a concentration of 2.5 mg / mL.

[0051] Table 2 Experimental sample addition table Test tube number 1 (Yang) 2 (overcast) 3-4 (Test sample) 2% red blood cell suspension mL 2.5 2.5 2.5 0.9% sodium chloride solution mL / 2.5 2.0 Purified water mL 2.5 / / Test solution mL / / 0.5 The results are as follows Fig.11 As shown in the figure, after 3 hours of incubation, the solution in the No. 1 positive control was clear red, hemolysis occurred, a small amount of red blood cells remained, and no red blood cell aggregation occurred. The red blood cells in the No. 2 negative control tube, No. 3 sample tube, and No. 4 sample tube all sank, the supernatant liquid was colorless and clear, dispersed after shaking, and no hemolysis occurred; under the conditions of this experiment, the two groups of polypeptides did not cause hemolysis and red blood cell aggregation reactions, and the results were negative.

[0052] Example 5: Effect of polypeptide on subcutaneous tumor formation in nude mice with lung cancer BALB / C-Nu nude mice (SPF grade) were selected. After subcutaneous inoculation of tumor cells A549, when the average tumor size reached about 50 mm 3 At the same time, the model mice were randomly divided into two groups, with 5 mice in each group. According to the weight of the mice, the dosage was 20 mg / kg. The state of the model mice was observed every two days, and PBS and the polypeptide solution of the present invention were injected into the tumor with an extremely fine needle. The tumor size and mouse weight were recorded once, and the mice were killed on the 24th day. After the mice were killed, the tumors were collected and weighed.

[0053] The results are as follows Fig.12 , 13 As shown in Figure 2, with the extension of administration time, the tumor volume showed obvious differences ( p <0.001). In the later period of administration, black scabs appeared on the tumor site of mice. The results showed that the polypeptide can kill tumor cells in vivo; after the end of the in vivo administration experiment cycle, the nude mice were dissected and the tumors were weighed. It was found that the average weight and size of the tumor in the polypeptide group were smaller than those in the PBS group. The results showed that the polypeptide of the present invention can kill tumors in vivo and can effectively control the weight and size of tumors.

[0054] Example 6: Effect of peptide combined with chemotherapy drugs on lung cancer A549 cells A 3.2 μg / ml doxorubicin (DOX) solution, a 0.1 μg / mL docetaxel (DTX) solution, a 64 μg / mL cisplatin (Pt) solution, and an 80 μg / mL polypeptide solution of the present invention were prepared respectively, and then diluted with RPMI 1640 complete medium to obtain several concentration gradients, thereby preparing the concentration for combined application.

[0055] A549 cells were used as receptors. The specific concentrations and operation methods were as follows: single-drug group: 100 μL of drug-containing solution was added to a 96-well plate, including a single-drug peptide group (3 concentrations of 40, 20, and 10, in μg / mL), a single-drug DOX group (6 concentrations of 2.5, 0.5, 0.1, 0.02, 0.0040, and 0.0008, in μg / mL), a single-drug DTX group (6 concentrations of 0.03258, 0.00652, 0.00130, 2.61×10 -4 , 5.21×10 -5 , 1.04×10 -5 , unit is μg / mL), single drug Pt group (6 concentrations are 50, 10, 2, 0.4, 0.08, 0.016, unit is μg / mL). Combination drug group: 50 μL of polypeptide solution and 50 μL of DOX solution or DTX solution or Pt solution were added to the 96-well plate, respectively, and the three concentrations of the polypeptide of the present invention were combined with the six concentrations of three different chemotherapy drugs, and the 96-well plate was shaken slowly to fully mix the two drugs in the wells to ensure that the final concentration in the combination drug was the same as the single drug concentration. Set up a blank group (containing only complete culture medium) and a control group (cells and complete culture medium), and each of the above groups has 3 replicates. The periphery of the well plate was sealed to prevent the culture medium from volatilizing too quickly and affecting the cell state. After 48 hours of incubation, CCK-8 was used for detection.

[0056] Results The Combination Index (CI) and Dose Reduction Index (DRI) were calculated using Compusyn software to evaluate the synergistic effect of peptides and three common chemotherapy drugs. CI is used to evaluate the relationship between single drugs in combination therapy; with 1 as an evaluation standard, CI values ​​less than 1, greater than 1, and equal to 1 represent synergy, antagonism, and additive effects, respectively. The smaller the CI value, the stronger the synergy between the two drugs. DRI represents the dose reduction multiple of each drug combination compared with the single drug.

[0057] like Fig.14 As shown in Figure 2, with the increase of concentration, the cell survival rate showed an overall downward trend, and the IC values ​​of the three chemotherapeutic drugs were obtained. 50 values ​​(Table 3).

[0058] Table 3 IC of chemotherapy drugs 50 value Name of chemotherapy drug <![CDATA[IC 50 Value (μg / mL)]]> DOX 0.1022 DTX 0.001303 Pt 1.823 like Fig.15 As shown, the cell inhibition rates of the three groups after combined use were mostly higher than those of single drugs, among which the dosage curve of the DTX combined use group was the most regular, and the increase in cell inhibition rate of the combined group was generally larger.

[0059] like Fig.16 As shown, the CI values ​​of the three combined drug groups are generally less than 1, among which the DTX combined drug group is all less than 1, and most of them are less than 0.5, which indicates that there is a strong synergistic effect between the polypeptide of the present invention and DTX; the DRI values ​​of the combined groups are almost all greater than 1, indicating that the polypeptide of the present invention can improve the therapeutic efficiency of the three chemotherapeutic drugs. Among them, the DRI values ​​of the DTX combined drug group are all greater than 1, indicating that the polypeptide of the present invention has more advantages in reducing the dosage of drugs after being used in combination with DTX.

[0060] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on parts thereof. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention. Although the above describes the specific implementation methods of the present invention, it is not intended to limit the protection scope of the present invention. Those skilled in the art should understand that, based on the technical solution of the present invention, various modifications or deformations that can be made by those skilled in the art without creative labor are still within the protection scope of the present invention.

Claims

1. A polypeptide, characterized in that: The amino acid sequence of the polypeptide is SEQ ID NO.

1.

2. Use of the polypeptide according to claim 1 in preparing a drug for treating lung cancer.

3. The use according to claim 2, characterized in that: The polypeptide can be used in combination with any one or a combination of alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immunosuppressants, doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt), preferably DOX, DTX or Pt.

4. A composition for treating lung cancer, characterized in that: Containing the polypeptide according to claim 1.

5. The composition according to claim 4, characterized in that: The composition further includes a pharmaceutically acceptable excipient.

6. The composition according to claim 4 or 5, characterized in that: The dosage form of the composition includes oral preparations or injections.

7. The composition according to claim 6, characterized in that: The oral preparations include tablets, capsules, granules, pills, syrups, sprays, aerosols, oral solutions, oral suspensions or oral emulsions.

8. The composition according to claim 6, characterized in that: The injection preparation includes injection solution or powder injection.

9. The composition according to claim 4, characterized in that: The polypeptides can be used in combination with chemotherapeutic drugs.

10. The composition according to claim 9, characterized in that: The chemotherapy drugs include alkylating agents, antimetabolites, antitumor antibiotics, plant anticancer drugs, hormones, immunosuppressants, doxorubicin (DOX), docetaxel (DTX) or cisplatin (Pt) in any one or a combination of several of them, preferably DOX, DTX or Pt.